Nonacus

Executive Summary

Nonacus is a UK-based biotechnology company specializing in liquid biopsy next-generation sequencing (NGS) solutions for oncology and hereditary disease diagnostics. Founded in 2015 and headquartered in Birmingham, the company develops end-to-end validated workflows, including in vitro diagnostic (IVD) kits and research-use-only (RUO) products, as well as clinical testing services. Its non-invasive genomic analysis approach aims to improve patient outcomes by enabling early detection, monitoring, and personalized treatment decisions. Nonacus operates in the rapidly growing liquid biopsy market, which is driven by increasing demand for non-invasive cancer screening and precision medicine. The company's technology addresses key challenges in sensitivity and specificity, positioning it as a potential competitor to larger diagnostic firms. While still private and early-stage, Nonacus has a clear focus on commercializing its assays and expanding its clinical footprint, particularly in Europe and potentially the US. Its success hinges on regulatory approvals, clinical validation, and strategic partnerships to scale adoption.

Upcoming Catalysts (preview)

• Q3 2026CE-IVD Certification for Key Oncology Panel70% success
• Q4 2026Strategic Partnership with Major Pharma for Clinical Trial Use60% success
• Q1 2027Series B Funding Round for International Expansion55% success